Spero Financial Statements From 2010 to 2026

Spero Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 120.1 M 127.1 M 80.9 M Slightly volatile Other Current Liabilities 11.6 M 20.4 M 9.4 M Slightly volatile Total Current Liabilities 59.3 M 56.4 M 20.5 M Slightly volatile Total Stockholder Equity 80.9 M 53 M 51.2 M Slightly volatile Other Liabilities 26.9 M 25.6 M 10.9 M Slightly volatile Property Plant And Equipment Net 4.7 M 3.6 M 3.3 M Slightly volatile Current Deferred Revenue 13.6 M 25.4 M 6.6 M Slightly volatile Accounts Payable 8.8 M 8.4 M 3.1 M Slightly volatile Cash 66.4 M 60.8 M 44.6 M Slightly volatile Non Current Assets Total 3.6 M 3.8 M 8.5 M Slightly volatile Non Currrent Assets Other 167.2 K 175.9 K 2.5 M Pretty Stable Other Assets 1.09 1.15 1.4 M Pretty Stable Cash And Short Term Investments 89.4 M 60.8 M 58.3 M Slightly volatile Net Receivables 63.4 M 60.3 M 14.8 M Slightly volatile Common Stock Shares Outstanding 65.3 M 62.1 M 24 M Slightly volatile Liabilities And Stockholders Equity 120.1 M 127.1 M 80.9 M Slightly volatile Non Current Liabilities Total 17.6 M 17.6 M 11.8 M Slightly volatile Other Current Assets 2.1 M 2.2 M 3.5 M Slightly volatile Other Stockholder Equity 337.5 M 581.6 M 234.6 M Slightly volatile Total Liabilities 39.7 M 74.1 M 30.1 M Slightly volatile Deferred Long Term Liabilities 262.9 K 363.4 K 222.6 K Slightly volatile Property Plant And Equipment Gross 6.2 M 7.7 M 4.4 M Slightly volatile Total Current Assets 105.7 M 123.4 M 71.7 M Slightly volatile Short Term Debt 1.2 M 2 M 977.8 K Slightly volatile Property Plant Equipment 3.9 M 6.3 M 3.2 M Slightly volatile Non Current Liabilities Other 95 K 100 K 6.6 M Pretty Stable Common Stock 47 K 49.5 K 3.3 M Slightly volatile Noncontrolling Interest In Consolidated Entity 284 K 319.5 K 348.7 K Slightly volatile Common Stock Total Equity 21.7 K 33.4 K 20.5 K Slightly volatile Capital Surpluse 307.8 M 471.2 M 282.8 M Slightly volatile Additional Paid In Capital 145.1 M 163.3 M 178.2 M Slightly volatile Net Invested Capital 72.4 M 41.5 M 84.1 M Pretty Stable Net Working Capital 77.3 M 52.4 M 87.6 M Very volatile Capital Stock 41.3 K 63.2 K 29.6 K Slightly volatile Short and Long Term Debt Total 5 M 3.9 M 5.6 M Pretty Stable Long Term Debt Total 170.4 K 159.3 K 217.9 K Slightly volatile Capital Lease Obligations 5 M 3.9 M 5.6 M Pretty Stable
Spero Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 2.2 K 2.3 K 265.7 K Slightly volatile Selling General Administrative 21.6 M 26.3 M 15 M Slightly volatile Other Operating Expenses 74.1 M 139.5 M 56.1 M Slightly volatile Research Development 116.8 M 111.3 M 45.9 M Slightly volatile Cost Of Revenue 116.8 M 111.3 M 35.6 M Slightly volatile Total Operating Expenses 26.9 M 28.3 M 38 M Slightly volatile Preferred Stock And Other Adjustments 4.9 M 5.5 M 6 M Slightly volatile Reconciled Depreciation 1.7 K 1.8 K 394.8 K Pretty Stable Non Operating Income Net Other 1.2 M 749.7 K 1.4 M Slightly volatile Selling And Marketing Expenses 531.2 K 712.8 K 731.2 K Slightly volatile
Spero Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Sale Purchase Of Stock 8.8 M 9.3 M 24.9 M Pretty Stable Stock Based Compensation 5.2 M 9 M 3.6 M Slightly volatile Begin Period Cash Flow 60.6 M 87.8 M 41.2 M Slightly volatile Depreciation 2.2 K 2.3 K 333.3 K Slightly volatile End Period Cash Flow 66.4 M 60.8 M 44.6 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 1.27 1.33 109 Slightly volatile Dividend Yield 0.0031 0.0035 0.0038 Slightly volatile PTB Ratio 1.32 1.39 138 Slightly volatile Days Sales Outstanding 289 459 303 Pretty Stable Stock Based Compensation To Revenue 0.18 0.19 0.3923 Slightly volatile Capex To Depreciation 54.44 51.85 27.8173 Slightly volatile PB Ratio 1.32 1.39 138 Slightly volatile Payables Turnover 16.65 11.92 15.8651 Slightly volatile Sales General And Administrative To Revenue 0.52 0.55 10.5199 Slightly volatile Research And Ddevelopement To Revenue 2.2 2.32 36.212 Slightly volatile Capex To Revenue 19.81 18.86 8.2656 Slightly volatile Cash Per Share 1.07 1.13 4.1261 Very volatile Days Payables Outstanding 30.11 31.69 21 K Slightly volatile Current Ratio 2.39 2.51 3.8104 Slightly volatile Receivables Turnover 0.78 0.82 3.8185 Pretty Stable Shareholders Equity Per Share 0.93 0.98 3.6161 Very volatile Debt To Equity 0.0599 0.0838 0.0743 Very volatile Capex Per Share 1.97 1.87 0.7467 Slightly volatile Revenue Per Share 0.6 0.8 0.496 Slightly volatile Interest Debt Per Share 0.0869 0.0914 0.1483 Pretty Stable Debt To Assets 0.0493 0.0447 0.049 Slightly volatile Graham Number 3.55 4.0 4.3651 Slightly volatile Operating Cycle 268 459 293 Pretty Stable Price Book Value Ratio 1.32 1.39 138 Slightly volatile Days Of Payables Outstanding 30.11 31.69 21 K Slightly volatile Ebt Per Ebit 0.82 0.84 0.9902 Pretty Stable Effective Tax Rate 0.0966 0.092 0.0569 Slightly volatile Company Equity Multiplier 2.62 2.76 14.0524 Slightly volatile Total Debt To Capitalization 0.0556 0.0767 0.069 Very volatile Debt Equity Ratio 0.0599 0.0838 0.0743 Very volatile Quick Ratio 2.39 2.51 3.8989 Slightly volatile Net Income Per E B T 0.66 0.81 0.8273 Slightly volatile Cash Ratio 1.18 1.24 2.5856 Pretty Stable Days Of Sales Outstanding 289 459 303 Pretty Stable Free Cash Flow Operating Cash Flow Ratio 1.12 1.15 1.0307 Slightly volatile Price To Book Ratio 1.32 1.39 138 Slightly volatile Fixed Asset Turnover 14.56 13.87 5.0758 Slightly volatile Debt Ratio 0.0493 0.0447 0.049 Slightly volatile Price Sales Ratio 1.27 1.33 109 Slightly volatile Asset Turnover 0.41 0.39 0.1567 Slightly volatile Price Fair Value 1.32 1.39 138 Slightly volatile
Spero Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 47.6 M 50.1 M 121.2 M Pretty Stable

Spero Fundamental Market Drivers

Spero Upcoming Events

About Spero Therapeutics Financial Statements

Pair Trading with Spero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:

How To Invest In Spero Details

Is Spero Stock a good investment? Details

What is Spero Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details